Table 2.
Associations between genotype and breast cancer risk for six SNPs
| Marker | Chromosome position | Stagea | Cases/controls | MAFb | Per-allele OR (95% CI) | Heterozygous OR (95% CI) |
Homozygous OR (95%CI) |
Pvaluec |
|
|---|---|---|---|---|---|---|---|---|---|
| Stage | Combined | ||||||||
| rs1011970 G/T | 9 22,052,134 |
Stage 1 | 3,730/4,894 | 0.16 | 1.20 (1.11–1.30) |
1.19 (1.08–1.31) |
1.45 (1.13–1.86) |
2.6 × 10−5 | |
| Stage 2 | 12,253/12,000 | 0.17 | 1.09 (1.04–1.14) |
1.07 (1.01–1.13) |
1.29 (1.12–1.50) |
0.00026 | 2.5 × 10−8 | ||
| rs2380205 C/T | 10 5,926,740 |
Stage 1 | 3,730/4,895 | 0.44 | 0.86 (0.81–0.92) |
0.86 (0.78–0.95) |
0.75 (0.66–0.85) |
7.9 × 10−5 | |
| Stage 2 | 12,235/11,961 | 0.43 | 0.94 (0.91–0.98) |
0.95 (0.90–1.01) |
0.89 (0.82–0.95) |
0.0017 | 4.6 × 10−7 | ||
| rs10995190 G/A | 10 63,948,688 |
Stage 1 | 3,731/4,891 | 0.14 | 0.76 (0.70–0.84) |
0.77 (0.69–0.86) |
0.55 (0.40–0.77) |
6.1 × 10−8 | |
| Stage 2 | 12,261/12,000 | 0.15 | 0.86 (0.82–0.91) |
0.84 (0.79–0.89) |
0.83 (0.69–1.00) |
1.4 × 10−8 | 5.1 × 10−15 | ||
| rs704010 G/A | 10 80,511,154 |
Stage 1 | 3,726/4,893 | 0.39 | 1.15 (1.09–1.23) |
1.05 (0.95–1.15) |
1.38 (1.22–1.57) |
3.5 × 10−6 | |
| Stage 2 | 12,222/11,992 | 0.39 | 1.07 (1.03–1.11) |
1.11 (1.05–1.17) |
1.13 (1.04–1.21) |
0.00026 | 3.7 × 10−9 | ||
| rs614367 C/T |
11 69,037,945 |
Stage 1 | 3,723/4,882 | 0.15 | 1.30 (1.20–1.41) |
1.24 (1.13–1.37) |
2.02 (1.56–2.64) |
3.9 × 10−8 | |
| Stage 2 | 12,114/11,967 | 0.15 | 1.15 (1.10–1.20) |
1.16 (1.10–1.23) |
1.27 (1.10–1.47) |
1.3 × 10−8 | 3.2 × 10−15 | ||
a
Stage 2 includes genotype data in SEARCH, RBCS and FBCS together with publicly available data from CGEMS.
b
MAF, frequency of the minor (second listed) allele.
c
Adjusted 1-d.f. P trend (see Online Methods).